Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ERN1 | O75460 | 2/20 | 0.45 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628664 | 0.85 | ALDH1A1 (0.47) | ALDH1A1ERN1KDM4ETSHRTDP1 | |
| SCHEMBL4011543 | 0.85 | ALDH1A1 (0.47) | ALDH1A1ERN1KDM4ETSHRTDP1 | |
| SCHEMBL4898660 | 0.84 | ALDH1A1 (0.50) | POLBALDH1A1ERN1KDM4ETSHR | |
| SCHEMBL8731801 | 0.83 | POLB (0.44) | POLBALDH1A1ERN1KDM4ETSHR | |
| SCHEMBL4520879 | 0.83 | ALDH1A1 (0.40) | POLBALDH1A1ERN1KDM4ETSHR | |
| SCHEMBL31474876 | 0.82 | ALDH1A1 (0.56) | POLBALDH1A1ERN1KDM4ETSHR | |
| SCHEMBL269268 | 0.82 | ALDH1A1 (0.56) | POLBALDH1A1ERN1KDM4ETSHR | |
| SCHEMBL19330829 | 0.81 | ALDH1A1 (0.47) | ALDH1A1ERN1KDM4ETSHRTDP1 | |
| SCHEMBL194593 | 0.81 | ALDH1A1 (0.47) | POLBALDH1A1ERN1KDM4ETSHR | |
| SCHEMBL1030266 | 0.81 | POLB (0.47) | POLBALDH1A1AMY1AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110606855-B | Polysubstituted benzothienoisoquinoline, derivative and synthesis method thereof | 湘潭大学 | 2022-03-18 | — | — | CN | claimed |
| CN-113698365-A | Preparation method of cefditoren side chain | 成都大学 | 2021-11-26 | — | — | CN | claimed |
| CN-110606855-A | Polysubstituted benzothienoisoquinoline, derivative and synthesis method thereof | 湘潭大学 | 2019-12-24 | — | — | CN | claimed |
| US-12173018-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-114746418-B | Monocyclic beta-lactam compounds and uses thereof | 苏州信诺维医药科技股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4389752-A1 | CAMPTOTHECIN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-06-26 | — | — | EP | disclosed |
| CN-118063409-A | Preparation method of cefdinir and intermediate thereof | 江苏美迪克化学品有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117693511-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117069569-A | Method for preparing 2-chloro-3-hydroxy-4-methoxybenzaldehyde by adopting dynamic tubular reactor | 济南大学 | 2023-11-17 | — | — | CN | disclosed |
| US-4359464-A | 3-Furylmethyl-6-halo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines and antihypertensive use thereof | SMITHKLINE BECKMAN CORPORATION (US) | 1982-11-16 | — | — | US | disclosed |
| US-4352754-A | HYPOTENSIVE, ANTI-PARKINSON | SMITHKLINE CORPORATION (US) | 1982-10-05 | — | — | US | disclosed |
| US-4255422-A | DIURETICS, TREATMENT OF CARDIOVASCULAR DISORDERS | SMITHKLINE CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |
| US-4206210-A | PARKINSON'S DISEASE | SMITHKLINE CORPORATION (US) | 1980-06-03 | — | — | US | disclosed |
| US-4192872-A | ANTI -PARKINSONISM ACTIVITY | SMITHKLINE CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
| US-4172890-A | CARDIOVASCULAR, PARKINSON'S DISEASE, DOPAMINERGIC | SMITHKLINE CORPORATION (US) | 1979-10-30 | — | — | US | disclosed |
| US-4160765-A | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds | SMITHKLINE CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| US-4108989-A | TREATING PARKINSON*S DISEASE, CARDIOVASCULAR DISORDERS | SMITHKLINE CORPORATION (US) | 1978-08-22 | — | — | US | disclosed |
| US-4104379-A | DOPAMINERGIC ACTIVITY | SMITHKLINE CORPORATION (US) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12173018-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | POLB 2001/4885ALDH1A1 2794/4885ERN1 1534/4885 |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | POLB 2001/4885ALDH1A1 2794/4885ERN1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.